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the GTV was undertaken on the images to quantify entropy, 
uniformity, mean grey-level intensity, kurtosis, standard 
deviation of histogram and skewness for fine to coarse 




Results: To date, 23 patients from 21 centres entered in the 
trial have been analysed. Mean Grey Level <399.745, 
Skewness >2.215, Kurtosis >0.6 were associated with 
improved PFS (p=0.0227, p=0.0218, p=0.0460 respectively) 
for medium filter 3.0. For filter 4.0, improved PFS was 
associated with Mean Grey Level <454.055 (p=0.0227) and 
Skewness >0.840 (p=0.0371). Mean Grey Levels of <565.535 
(p=0.0251) and <542.5(p=0.0251) were associated with 
improved PFS for filters 5.0 and 6.0 respectively. For OS, 
mean grey levels of <34.845 (p=0.0182), <399.745 (p=0.0381) 
and <454.055 (p=0.0381) were associated with improved 
survival for filters 0.0, 3.0 and 4.0 respectively. An entropy 
level <5.6 was also found to be significant (p=0.0428) for 
improved overall survival using filter 2.0. 
 
Conclusion : Normal 0 false false false EN-GB JA X-NONE  
We have shown using a 10% sample of the overall database 
available that CTimage heterogeneity factors are associated 
with PFS and OS for patients frommultiple centres. 
Preliminary results therefore suggest that in the future itmay 
be possible to make clinical treatment decisions based on the 
CT imageheterogeneity of a tumour volume. This will be 
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Purpose or Objective: To evaluate the feasibility and clinical 
results of stereotactic body radiation therapy (SBRT) in the 
treatment of hepatocellular carcinoma (HCC) in patients 
unsuitable or failing to standard loco-regional therapies. 
 
Material and Methods: Patients with < 3 inoperable HCC 
lesions with < 6 cm diameter were treated with SBRT. 
Prescription dose was adapted according to tumor size and 
global liver function and comprised 48-36 Gy in 3 fractions or 
40 Gy in 5 fractions (prescribed on 80 % isodose). Primary 
endpoint included in-field (LC) local control and toxicity. 
Secondary endpoints were overall (OS), cancer-specific (CSS) 
and progression-free survival (PFS). 
 
Results: 82 patients with 120 HCC lesions were treated. 
Median age was 70 (range 44-90). Most of the patients had 
Child-Pugh A5-A6 cirrhosis (80.4%), Barcelona Clinic Liver 
Cancer classification 0-A-B (93%). Median lesion size was 22 
mm (range 7-120 mm). Most lesion were in the left lobe 
(65%). In most patients SBRT was the first local treatment 
(82%). Up to 7% of patients had portal vein thrombosis. 
Median observation time was 14 months. Actuarial 1-year LC, 
PFS, CSS and OS were 76.7% (95%CI:40-92.5%), 13.5% 
(95%CI:4.9-26-4), 92.1% (95%CI:81.8-96.7%) and 78% 
(95%CI:66.4-86%), respectively. Up to 18 patients (22%) 
experienced G3-G4 acute toxicity and 1 case of G5 toxicity 
was reported. Four cases of classical Radiation-induced liver 
disease (RILD) were reported, while 21 patients experienced 
a modification of Child-Pugh classification (25%), mostly of 2-
3 points. On multivariate analysis, no factors were predictive 
for LC while initial Child-Pugh class and > 2 points Child-Pugh 
classification modification predicted for OS and CSS. 
 
 
Conclusion: SBRT is a safe and effective treatment option for 
inoperable HCC, with acceptable LC rate and toxicity profile. 
Limiting toxic events may have prognostic significance. 
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